Announcing our newest partnership! We are collaborating with Sanofi to focus on targets in both immunology and oncology, using our small molecules targeting RNA platform. endpts.com/bill-haneys-la…

biopharmadive.com/news/rna-small… #drugdiscovery #RNA #smallmolecules

Proud day! Dragonfly Therapeutics Initiates Phase 2 Study of HER2 Targeting TriNKET® DF1001 prnewswire.com/news-releases/…

Yesterday, first patients dosed in our Her2-targeting TriNKET Phase 2 study. Today, first patient dosed in our EGFR-targeting TriNKET Phase 1 study. Let's go! #Immunoonc prnewswire.com/news-releases/…

A short but growing list of companies is seeking to drug RNA using small molecules. Driving interest is the knowledge that drugging RNAs could, in theory, expand the target landscape by almost two orders of magnitude go.nature.com/45ht24c

We love this! Thank you to Genentech, one of our partners, for sponsoring this brilliant initiative. endpts.com/genentech-spon…

We are delighted to announce approval for Skyhawk's Phase 1 of our RNA-Targeting Small Molecule for Huntington's disease.. prn.to/4979p0i

Maura McCarthy, of Skyhawk Therapeutics, commented on a new phase 1 study assessing #SKY-0515, a small molecule candidate as a potential treatment for #HuntingtonDisease. #MovementDisorders #NeruologyNews #ExpertInsight View: neurologylive.com/view/greater-i…

We moved! So wonderful to be all together under one roof, in a beautiful new facility. Ribbon Cutting Ceremony today, with CEO Bill Haney doing the honors.

Our Waltham HQ Team has moved! Ribbon Cutting Ceremony & Celebration in our beautiful new facility.

SKY-0515 is a small molecule RNA splicing modifier developed with our novel SKYSTAR® platform, now advanced into the Multiple Ascending Dose portion of its phase 1 study for Huntington's disease! prnewswire.com/news-releases/…

Skyhawk Therapeutics is pleased to announce the recent promotion of Clint Musil from Chief Financial Officer to Chief Executive Officer and the appointment of Bill Haney as Executive Chairman of the Board of Directors, effective February 2024. globenewswire.com/news-release/2…

Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction skyhawktx.com/post/skyhawk-t…

Skyhawk Therapeutics is pleased to present additional topline data from Parts A and B of its Phase 1 clinical trial of SKY-0515 at the European Huntington’s Disease Network and Enroll-HD 2024 meeting in Strasbourg, France. prnewswire.com/news-releases/…

Skyhawk Therapeutics is pleased to present at the upcoming EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium highlighting preclinical data on SKY-1214 being developed for difficult to treat multiple myeloma and non-Hodgkin’s lymphoma. prnewswire.com/news-releases/…

John Carroll Trailer is: youtube.com/watch?v=ruJdHT…

Screening of our CEO Bill Haney's new movie documentary at #JPM25, featuring the wonderful Phil Sharp Massachusetts Institute of Technology (MIT), Nobel Prize winning RNA & splicing guru, and the Biotech Revolution (with many other impressive folks). Thank you John Carroll for doing the Q&A (and being in the film!)

Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO International Congress in Prague, Czech Republic. #hdyocongress

Skyhawk and Dragonfly Tx are excited to be attending #BIOEuropeSpring this week in Milan!

Dear Skyhawk friends and colleagues - In honor of BIO Boston next Tuesday June 17th we are hosting a special private screening of Bill Haney's new film, Cracking the Code: Phil Sharp and the Biotech Revolution, at Boston's ICA: RSVP here! uncommonproductions.com/cracking-the-c…